[go: up one dir, main page]

DE69632815D1 - gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER - Google Patents

gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER

Info

Publication number
DE69632815D1
DE69632815D1 DE69632815T DE69632815T DE69632815D1 DE 69632815 D1 DE69632815 D1 DE 69632815D1 DE 69632815 T DE69632815 T DE 69632815T DE 69632815 T DE69632815 T DE 69632815T DE 69632815 D1 DE69632815 D1 DE 69632815D1
Authority
DE
Germany
Prior art keywords
antibodies
gc1q
region
related peptides
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69632815T
Other languages
English (en)
Other versions
DE69632815T2 (de
Inventor
S Fung
N Sun
R Sun
Woo Kim
Liming Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Tanox Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Biosystems Inc filed Critical Tanox Biosystems Inc
Application granted granted Critical
Publication of DE69632815D1 publication Critical patent/DE69632815D1/de
Publication of DE69632815T2 publication Critical patent/DE69632815T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69632815T 1995-03-24 1996-03-22 gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER Expired - Fee Related DE69632815T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/410,360 US5691447A (en) 1995-03-24 1995-03-24 GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
US410360 1995-03-24
PCT/US1996/003905 WO1996030400A1 (en) 1995-03-24 1996-03-22 THE gC1q RECEPTOR, HIV-1 gp120 REGION BINDING THERETO, AND RELATED PEPTIDES AND TARGETING ANTIBODIES

Publications (2)

Publication Number Publication Date
DE69632815D1 true DE69632815D1 (de) 2004-08-05
DE69632815T2 DE69632815T2 (de) 2005-07-14

Family

ID=23624383

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69632815T Expired - Fee Related DE69632815T2 (de) 1995-03-24 1996-03-22 gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER

Country Status (9)

Country Link
US (5) US5691447A (de)
EP (1) EP0815125B1 (de)
JP (1) JPH11502414A (de)
KR (1) KR100415423B1 (de)
CN (2) CN1221566C (de)
AT (1) ATE270303T1 (de)
AU (1) AU5320196A (de)
DE (1) DE69632815T2 (de)
WO (1) WO1996030400A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2284084A1 (en) * 1997-03-12 1998-09-17 Institut Pasteur A novel cell surface receptor for hiv retroviruses, therapeutic and diagnostic uses
AU770033B2 (en) * 1997-08-06 2004-02-12 Genset S.A. Lipoprotein-regulating medicaments
FR2767136B1 (fr) * 1997-08-06 2004-08-27 Genset Sa Recepteur complexe lsr, activite, clonage, et applications au diagnostic, a la prevention et/ou au traitement de l'obesite et des risques ou complications associes
AU2004201889B2 (en) * 1997-08-06 2007-06-21 Institut National De La Sante Et De La Recherche Medicale Lipoprotein-regulating medicaments
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
JP2000023286A (ja) * 1998-07-02 2000-01-21 Murata Mfg Co Ltd スピーカ
DE69938837D1 (de) 1998-11-04 2008-07-10 Serono Genetics Inst Sa Genomische und vollständige cdna sequenzen von menschlichem adipozyten spezifischem apm1 und biallelische marker davon
EP1153139B1 (de) 1999-02-10 2009-04-01 Serono Genetics Institute S.A. Polymorphe marker des lsr-gens
EP1214351A2 (de) 1999-09-22 2002-06-19 Genset Verfahren zur selektion von verbindungen, die die wechselwirkung zwischen leptin und lsr modulieren, und ihre verwendung für die verhütung und behandlung von fettsuchtverwandten krankheiten
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en) 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
US7162302B2 (en) * 2002-03-04 2007-01-09 Nanoset Llc Magnetically shielded assembly
US7091412B2 (en) * 2002-03-04 2006-08-15 Nanoset, Llc Magnetically shielded assembly
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
AU2003248724A1 (en) * 2002-06-26 2004-01-19 University Of Louisville Research Foundation, Inc. A method for the detection of apoptosis
CA2492883C (en) 2002-08-01 2012-10-02 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20050155779A1 (en) * 2003-04-08 2005-07-21 Xingwu Wang Coated substrate assembly
US20050119725A1 (en) * 2003-04-08 2005-06-02 Xingwu Wang Energetically controlled delivery of biologically active material from an implanted medical device
US20060118758A1 (en) * 2004-09-15 2006-06-08 Xingwu Wang Material to enable magnetic resonance imaging of implantable medical devices
CN101146554B (zh) 2005-01-27 2012-10-10 加州大学评议会 中和肉毒杆菌神经毒素的治疗性单克隆抗体
CA2657649A1 (en) * 2006-07-13 2008-08-21 Burnham Institute For Medical Research Methods and compositions for targeting gc1qr/p32
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
JP5142265B2 (ja) 2007-05-28 2013-02-13 独立行政法人産業技術総合研究所 抗モータリン抗体のパラトープ及びエピトープ
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
CN101885760B (zh) * 2010-03-16 2012-12-05 王世霞 密码子优化的HIV-1gp120基因共有序列及gp120核酸疫苗
PL3446714T3 (pl) 2011-06-02 2021-11-22 University Of Louisville Research Foundation, Inc. Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie
US10857237B2 (en) 2015-05-05 2020-12-08 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2853453A1 (de) * 1978-12-11 1980-06-19 Behringwerke Ag Mittel zur therapie von immunkomplexerkrankungen
US4595654A (en) * 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
CA2066607A1 (en) * 1989-09-22 1991-03-23 Thomas Kieber-Emmons Peptides associated with the cd4 binding region of gp120 and their methods of use
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
NZ267838A (en) * 1993-06-07 1997-12-19 Genentech Inc Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains

Also Published As

Publication number Publication date
JPH11502414A (ja) 1999-03-02
CN1179163A (zh) 1998-04-15
DE69632815T2 (de) 2005-07-14
US5652333A (en) 1997-07-29
EP0815125B1 (de) 2004-06-30
US5728814A (en) 1998-03-17
US5739306A (en) 1998-04-14
CN1508151A (zh) 2004-06-30
KR19980703260A (ko) 1998-10-15
US5731428A (en) 1998-03-24
CN1150207C (zh) 2004-05-19
KR100415423B1 (ko) 2004-04-21
EP0815125A1 (de) 1998-01-07
EP0815125A4 (de) 2002-01-02
WO1996030400A1 (en) 1996-10-03
AU5320196A (en) 1996-10-16
US5691447A (en) 1997-11-25
ATE270303T1 (de) 2004-07-15
CN1221566C (zh) 2005-10-05

Similar Documents

Publication Publication Date Title
DE69632815D1 (de) gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER
Porter Chemical structure of γ-globulin and antibodies
EP0651818A4 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung.
ATE290014T1 (de) Festphasen-peptidsynthese
BR9507618A (pt) Frações polipeptidicas solúveis da proteína lag-3 processo de produção composição terapêutica anticorpos anti-idiotipo
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
EP0673255A4 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon.
HUP0000318A2 (hu) Tumorvakcina és eljárás előállítására
ATE238065T1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
DK1071442T3 (da) Fremgangsmåder og præparater til peptidsyntese (T-20)
AU3526689A (en) Peptides that block the binding of hiv-1 to the cd4 receptor protein
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
Adler et al. T cell epitope analysis with peptides simultaneously synthesized on cellulose membranes: fine mapping of two DQ dependent epitopes
Abood et al. Interaction of putative vasopressin receptor proteins of rat brain and bovine pituitary gland with an antibody against a nanopeptide encoded by the reverse message of the complementary mRNA to vasopressin
Kukongviriyapan et al. Some parameters of affinity chromatography in the purification of antibody against Naja naja siamensis toxin 3
EP1200476A4 (de) Antitumorantikörper, proteine und deren verwendung
ATE260339T1 (de) Antikörper gegen menschliches restrictin
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
Marchalonis et al. Antigenic polypeptide fragments of a receptor related to the Fab fragment of human immunoglobulin from thymus-derived lymphocytes.
Escher et al. Preparation of non-crossreactive RIA for the three mammalian tachykinins SP, NKA and NKB
MX9803086A (es) Nuevo adn y proceso para preparar proteina usando el adn.
MX9700199A (es) Composiciones de cadena invariante utiles para tratar enfermedades autoinmunes.
IT1253882B (it) Procedimento per la identificazione e la sintesi di siti di interazione di proteine interagenti

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TANOX, INC. (N.D.GES.D. STAATES DELAWARE), HOUSTON

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GENENTECH, INC., SOUTH SAN FRANCISCO, CALIF., US

8339 Ceased/non-payment of the annual fee